Phase I/II Study of Metastatic Cancer Using Lymphodepleting Conditioning Followed by Infusion of Anti-mesothelin Gene Engineered Lymphocytes
Phase of Trial: Phase I/II
Latest Information Update: 26 May 2018
At a glance
- Drugs Aldesleukin (Primary) ; Cyclophosphamide (Primary) ; Fludarabine (Primary)
- Indications Cervical cancer; Lung cancer; Mesothelioma; Ovarian cancer; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- 20 Jul 2017 Planned primary completion date changed from 31 Dec 2018 to 4 Dec 2028.
- 20 Jul 2017 Planned End Date changed from 1 Dec 2019 to 31 Dec 2029.
- 05 Oct 2016 Status changed from suspended to recruiting.